Thirteen Thousand Six Hundred Miles

On July 29, 2026, a team of surgeons led by Sudhir Srivastava sat at a console in Bucaramanga, Colombia, and operated on a patient in Indore, India: a robotic sleeve gastrectomy performed across more than 13,600 miles, some 22,000 kilometres of fiber network distance. It broke a record his own company had set eight weeks earlier, when a robotic-assisted heart procedure crossed approximately 12,500 miles between Guyana and India. That one had broken a record set in early May, when a surgeon in Perth operated on a patient in Indore from more than 4,500 miles away, live, in front of the Royal Australian College of Surgeons.

Three distance records in three months.

None of them is the number Srivastava needs. That number is a date, and over the same stretch it moved nine months in the wrong direction.

The Date That Moved

On March 30, 2026, announcing regulatory clearance for the SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya, Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations International, gave the market a timetable. He anticipated that "the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for the SSi Mantra by mid-2026." European certification, he said in the same release, was on a path "which we believe we can obtain in 2026."

Mid-2026 arrived. Nothing was announced.

On August 13, filing second-quarter results, the company rewrote the sentence. It now expects the agency "to complete its review of our 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027." The European timetable was restated as the end of 2026.

Neither release explains the gap between the two dates. No regulatory action, favourable or otherwise, has been disclosed. Between the two statements the company reported record revenue, won an industry award, and twice broke its own record for the longest robotic operation ever performed at distance. What it did not get was the one clearance that would open the market its shares are priced against.

He Stopped Operating To Manufacture

The patience is at least well practised. Srivastava completed his medical degree in India in 1971 and moved to the United States the following year, taking a residency in general surgery in St. Louis and cardiothoracic training at the University of British Columbia Hospitals in Vancouver. He is double board certified by the American Board of Surgery and Thoracic Surgery. He began practising in Texas in 1981, and in 2002 became founding chairman of Alliance Hospital there, which company filings describe as among the busiest robotic cardiac centres in the world. In 2007 he joined the University of Chicago faculty as Director of Robotic Cardiac Surgery to launch its programme. In 2009 he moved to Atlanta and founded the International College of Robotic Surgery.

By the time he left North America he had performed over 1,400 robotic cardiothoracic procedures and trained over 350 surgical teams.

He returned to India in 2011. In 2012 he took the decision the entire company now rests on: rather than import machines priced for American hospitals, build one cheap enough to sell into Indian ones. The SSi Mantra reached the market in August 2022, ten years later. He was 64 when he started and 74 when it shipped.

Two Hundred And Twenty-Four Machines

The arithmetic since then has been steep. At June 30, 2026 the cumulative installed base stood at 224 systems across twelve countries, against 105 a year earlier. Cumulative surgeries reached 12,272, up from 4,657, including 637 cardiac procedures, 222 pediatric surgeries and 175 telesurgeries. Second-quarter revenue was $13,939,709, up 39.4 percent. First-half revenue was $25,041,075, up 65.6 percent. Long-term debt was zero.

His own summary opened the release: "SS Innovations delivered record quarterly revenue of $13.9 million in the second quarter of 2026, up 39% year over year, reflecting strong adoption of our advanced SSi Mantra surgical robotic system by leading hospitals and surgeons in India and abroad."

The argument underneath the numbers is access rather than novelty. After the Perth procedure in May he put it plainly: "We believe that telesurgery has the power to transform traditional healthcare delivery and democratize access to global surgical expertise."

The Margin Went The Other Way

Record revenue was not the whole quarter. Gross margin fell to 50.9 percent from 59.1 percent a year earlier, so gross profit rose 20.0 percent while revenue rose 39.4 percent. The net loss widened to $2.7 million from $0.3 million.

The mix explains most of it. System sales grew 40.8 percent, to $12.4 million. Instrument sales grew 13.4 percent, to $1.1 million. Those instruments are the recurring revenue meant to compound behind every machine sold, and in the same quarter the number of surgeries performed on SSi Mantra systems grew 142.6 percent. Consumables are not yet following the operating room. A company that sells hardware into hospitals faster than that hardware generates repeat orders is a company still funding its own installed base.

Cash and cash equivalents stood at $13.6 million at June 30, excluding restricted cash. Srivastava held 114,468,548 shares as of May 20, or 58.8 percent of the company. Whichever way the regulator moves, he owns most of the outcome.

What The Agency Has Not Said

The products he unveiled in New Delhi in April read like a different company's roadmap: a drone-deployed surgical system intended to reach wounded soldiers before evacuation, a humanoid platform, a mobile operating room on a wheeled chassis. "Innovation is in our DNA," he said, presenting them. None of the three has a disclosed regulatory pathway.

The machine that does is already in twelve countries and 224 hospitals. Its European certification is due by the end of 2026. Its American review is due by the end of the first quarter of 2027, a date that has been rewritten once already. In August he described the system as "engineered for precision, built to perform, and created to democratize access to advanced surgical robotic care" - the language of a manufacturer rather than a surgeon.

He can put a surgeon 13,600 miles from a patient and close the gap in milliseconds. The border he has not crossed is far shorter, and it does not yield to distance records.